Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement

European Heart Journal

Volumn 38, Issue 38, 2017, Pages 2879-2887

  Castano, Adam ^a   Narotsky, David L ^a   Hamid, Nadira ^a   Khalique, Omar K ^a   Morgenstern, Rachelle ^a   DeLuca, Albert ^a   Rubin, Jonah ^a   Chiuzan, Codruta ^b   Nazif, Tamim ^a   Vahl, Torsten ^a   George, Isaac ^a   Kodali, Susheel ^a   Leon, Martin B ^a   Hahn, Rebecca ^a   Bokhari, Sabahat ^a   Maurer, Mathew S ^a  

^a NewYork Presbyterian Hospital   (United States)

^b Mailman School of Public Health ^*  (United States)

Author keywords

Aortic stenosis; Low flow low gradient; Strain; TAVR; Transthyretin cardiac amyloidosis

Indexed keywords

PREALBUMIN; PYROPHOSPHATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT;

AGED; AORTIC STENOSIS; ARTICLE; CARDIAC PATIENT; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DISEASE SEVERITY; FEMALE; HEART AMYLOIDOSIS; HEART CONTRACTION; HEART SCINTISCANNING; HEART STROKE VOLUME; HUMAN; INTERVENTRICULAR SEPTUM; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRANSCATHETER AORTIC VALVE IMPLANTATION; TRANSTHORACIC ECHOCARDIOGRAPHY; VERY ELDERLY; AORTIC VALVE STENOSIS; BLOOD VESSEL CALCIFICATION; CARDIOMYOPATHY; COMPARATIVE STUDY; COMPLICATION; ECHOCARDIOGRAPHY; ETIOLOGY; FAMILIAL AMYLOID POLYNEUROPATHY; HEART LEFT VENTRICLE FUNCTION; PATHOPHYSIOLOGY; PHYSIOLOGY; SCINTISCANNING;

AGED, 80 AND OVER; AMYLOID NEUROPATHIES, FAMILIAL; AORTIC VALVE STENOSIS; CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; FEMALE; HUMANS; MALE; PHENOTYPE; PROSPECTIVE STUDIES; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; STROKE VOLUME; TECHNETIUM TC 99M PYROPHOSPHATE; TRANSCATHETER AORTIC VALVE REPLACEMENT; VASCULAR CALCIFICATION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85032748590     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehx350     Document Type: Article

References (29)

1. Thaden JJ, Nkomo VT, Enriquez-Sarano M. The global burden of aortic stenosis. Prog Cardiovasc Dis 2014;56:565-571.
2. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Lung B, Lancellotti P, Pierard L, Price S, Schafers HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M; ESC Committee for Practice Guidelines (CPG); Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology; European Association for Cardio-Thoracic Surgery. Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 2012;42:S1-S44.
3. Clark MA, Arnold SV, Duhay FG, Thompson AK, Keyes MJ, Svensson LG, Bonow RO, Stockwell BT, Cohen DJ. Five-year clinical and economic outcomes among patients with medically managed severe aortic stenosis results from a medicare claims analysis. Circ-Cardiovasc Qual 2012;5:697-704.
4. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, O'Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM 3rd, Thomas JD; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:e57-e185.
5. Dayan V, Vignolo G, Magne J, Clavel MA, Mohty D, Pibarot P. Outcome and impact of aortic valve replacement in patients with preserved LVEF and lowgradient aortic stenosis. J Am Coll Cardiol 2015;66:2594-2603.
6. Bavishi C, Balasundaram K, Argulian E. Integration of flow-gradient patterns into clinical decision making for patients with suspected severe aortic stenosis and preserved LVEF: A systematic review of evidence and meta-analysis. JACC Cardiovasc Imaging 2016;9:1255-1263.
7. Pibarot P, Dumesnil JG. Paradoxical low-flow, low-gradient aortic stenosis: new evidence, more questions. Circulation 2013;128:1729-1732.
8. Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, Berk JL, Seldin DC. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: A prospective, observational cohort study. Circulation 2016;133:282-290.
9. Castano A, Drachman BM, Judge D, Maurer MS. Natural history and therapy of TTR-cardiac amyloidosis: Emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev 2015;20:163-178.
10. Kristen AV, Schnabel PA, Winter B, Helmke BM, Longerich T, Hardt S, Koch A, Sack FU, Katus HA, Linke RP, Dengler TJ. High prevalence of amyloid in 150 surgically removed heart valves-a comparison of histological and clinical data reveals a correlation to atheroinflammatory conditions. Cardiovasc Pathol 2010;19:228-235.
11. Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: Characterization by a distinctive voltage/mass relation. Am J Cardiol 1982;49:9-13.
12. Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733-2779.
13. Phelan D, Collier P, Thavendiranathan P, Popovic ZB, Hanna M, Plana JC, Marwick TH, Thomas JD. Relative apical sparing of longitudinal strain using twodimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012;98:1442-1448.
14. Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, Gagliardi C, Milandri A, Rapezzi C, Falk RH. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation 2014;129:1840-1849.
15. King DL, El-Khoury Coffin L, Maurer MS. Myocardial contraction fraction: A volumetric index of myocardial shortening by freehand three-dimensional echocardiography. J Am Coll Cardiol 2002;40:325-329.
16. Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013;6:195-201.
17. Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, Ferlini A, Longhi S, Lorenzini M, Reggiani LB, Gagliardi C, Gallo P, Villani C, Salvi F. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2011;4:659-670.
18. Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, Pozniakoff T, Ruberg FL, Miller EJ, Berk JL, Dispenzieri A, Grogan M, Johnson G, Bokhari S, Maurer MS. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: Predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol 2016;1:880-889.
19. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-2412.
20. Suhr O, Danielsson A, Holmgren G, Steen L. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med 1994;235:479-485.
21. Bokhari S, Morgenstern R, Weinberg R, Kinkhabwala M, Panagiotou D, Castano A, DeLuca A, Andrew K, Jin Z, Maurer MS. Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis. J Nucl Cardiol 2016; doi: 10.1007/s12350-016-0610-4.
22. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:233-270.
23. Efron B, Tibshirani R. Improvements on cross validation: The .632 bootstrap method. J Am Stat Assoc 1997;92:548-560.
24. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Member. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-2200.
25. Longhi S, Lorenzini M, Gagliardi C, Milandri A, Marzocchi A, Marrozzini C, Saia F, Ortolani P, Biagini E, Guidalotti PL, Leone O, Rapezzi C. Coexistence of degenerative aortic stenosis and wild-type transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2016;9:325-327.
26. Treibel TA, Fontana M, Gilbertson JA, Castelletti S, White SK, Scully PR, Roberts N, Hutt DF, Rowczenio DM, Whelan CJ, Ashworth MA, Gillmore JD, Hawkins PN, Moon JC. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: Prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging 2016;9
27. Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral F, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:2585-2594.
28. Sperry BW, Jones BM, Vranian MN, Hanna M, Jaber WA. Recognizing transthyretin cardiac amyloidosis in patients with aortic stenosis: Impact on prognosis. JACC Cardiovasc Imaging 2016;9:904-906.
29. Satoskar AA, Efebera Y, Hasan A, Brodsky S, Nadasdy G, Dogan A, Nadasdy T. Strong transthyretin immunostaining: Potential pitfall in cardiac amyloid typing. Am J Surg Pathol 2011;35:1685-1690.